upsid price
return equiti ltm
note pleas refer page end
report import disclosur
top line varian gener revenu million versu estim
million consensu estim million oncolog system
revenu million versu estim million proton
solut segment deliv million revenu versu estim
million revenu million versu estim
million gross oncolog system order quarter increas report
constant currenc
increas price
outlook varian affirm previous provid financi guidanc
includ assumpt revenu growth organ revenu
growth non-gaap ep rang vs cash
flow oper rang million non-gaap effect tax
rate expect weight averag
share count around million current model
non-gaap ep
bottom line varian report non-gaap ep figur quarter
versu expect consensu estim also heavier-
than-anticip sg expens primari reason slight profit
miss rel model
balanc sheet cash flow varian end quarter cash
equival approxim million around million debt
flow oper quarter million capit expenditur
million
recommend maintain outperform invest rate
share increas price target arriv
price target attach multipl adjust ebitda estim
assum approxim million net cash month
revenu mil estimate bold
ep estimate bold
overal varian deliv larg in-lin result includ small top-lin beat
slight shortfal profit order momentum oncolog remain solid
growth dollar constant currenc varian manag also affirm
revenu look revenu oper segment oncolog system revenu came
million estim million revenu segment increas
versu compar period last year product revenu growth oncolog
system quarter servic increas whop result
enhanc recent
varian proton solut segment deliv million revenu declin around
versu compar quarter last year estim difficult-to-model
busi million
varian revenu segment deliv million revenu versu estim
gross margin oper expens total consolid gross margin came
versu estim non-gaap gross margin
increas bp versu last year compar quarter quarter result
benefit product mix tariff exclus partial off-set proton
busi project mix million updat project cost oncolog system
gener gross margin bp yoy proton busi gross
margin repres declin bp final revenu segment
gener gross margin quarter
sg expens came revenu expect non-
sg expens recent activ materi impact result
expect see leverag captur sg expens line next sever
quarter longer term well expens revenu
versu model
profit non-gaap ep came versu estim
consensu expect also
balanc sheet cash flow varian end quarter cash equival
approxim million million debt flow oper
million quarter versu period last year due
invest work capit
varian report solid quarter includ small revenu beat slight miss
term profit compani solid order momentum oncolog servic
continu manag affirm previous provid financi guidanc
despit recent run-up share price continu remain construct idea
near term longer term
remind varian financi guidanc includ expect
overal revenu growth includ organ growth non-gaap ep
vs non-gaap ep deliv non-gaap oper margin
rang oper cash flow million current
model non-gaap ep revenu growth
oncolog system revenu grew dollar constant currenc
quarter solid result driven strong growth servic softwar
includ revenu growth america region revenu growth
emea region report growth constant currenc increas
revenu asia-pacif region report growth constant currenc
oncolog system order grew report constant currenc
result roughli consist trail month perform order growth
overal momentum busi remain solid visibl seem good
continu strong perform next sever quarter
america gross oncolog order million increas
europ middl east india africa region gross oncolog order increas
dollar million constant currenc final gross oncolog
order asia-pacif region million dollar
constant currenc
compani net instal base radiat therapi stand unit
result repres growth versu period last year
win quarter includ seven radiotherapi system massachusett
gener hospit eight halcyon system brazil five halcyon system china five
truebeam system spain seven truebeam system singapor
compani state taken order three etho unit quarter
taken order etho unit last quarter shortli product
introduc import note etho commerci avail hand
market current approv anticip within next day
compani said earli feedback early-adopt etho custom
strong workflow superior repeatedli cite one
product key differenti feedback certainli align compani initi
hopes/expect product impact patient care
varian continu see strong demand high margin softwar solut
softwar revenu increas quarter uniqu softwar custom grew
approxim quarter approxim hardwar show growth
servic revenu aid materi recent activ
varian proton solut busi gener million revenu
quarter book one new order compani book five order past
three quarter gone year without book new proton
busi compani also disclos cancel one order india
previous book late
compani said continu encourag earli result
flashforward consortium remind earli preclin work flash technolog
shown promis amazingli quick treatment throughput attack
cancer tumor larg spare healthi tissu continu believ
initi could ultim success result genuin paradigm shift treatment
radiat therapi space
compani segment gener million quarter includ
var intervent oncolog busi run former varian cfo gari
cryoablat embol
microspher microwav ablat cardiac radioabl current expect mid-
upper single-digit growth segment forese futur
varian disclos growth china continu strong rel broad
base date varian said experienc materi neg impact
term order flow employe downtim coronaviru make
intern headlin past week
varian disclos experienc weak japan quarter
character normal oscil compani add howev higher
margin servic busi countri strong quarter
compani continu await guidanc regard plan
transit cancer care toward value-bas reimburs model manag
expect final rule current delay point strongli
believ varian well posit compet space continu
assess futur cancer care may best deliv price
varian expect captur leverag sg expens line remaind
year experienc somewhat elev sg expens level due
intern invest cost associ integr recent
compani continu activ share repurchas activ
repurchas share approxim million quarter
compani still million share remain current share repurchas
author quarter end
maintain outperform invest rate share
increas price target arriv price target attach
multipl adjust ebitda estim assum around
million net cash month
revenu
interest incom net
 revenu
sg revenu
million except per share data
ect utp rform th mar ket th ne xt mon th
un im pro ving co mpa fun da men ta ls
ect erfo rm ro ugh ly lin mark ver ext onth
lo ng -term oten tial exi st ea r- te rm catal yst ap pa ren
ect nd erp erfo rm rket ove ne xt mon th
com pan fu nd ame ntal de terio ra tin
fulli valu ver- va lu ed cu rre nt level
evelop ing pr ice ta rg et omp sed ev /eb itda th ere ho wever
risk ur tar ge rice wi chie ved th ese nclu de ut imit fa ilu
com pa ny ee ur ven ue ea rnin gs stim ate
foll owin list ra ting com pan ie cove red arri ng rese arch sso ciat
inc ecem ber um ber omp ani es ra te utp rfo rm nd
rep sent comp cov era ge li st th nu mbe co mpa nie ra ted
ke pe rfor ep rese nted co mpa nie th co vera ge list
 umb er comp ie ra ted und rp erfo rm pre sen te
comp cove ra ge list lso dece mbe ba rrin gto esea rch
asso ci ate inc ha ro vi de vestm nt ba nkin ser vi ce within th last mon th
 th co mpa nie th ad utp er fo rm atin gs th
comp tha ad mark et er fo rm ate nd co mpa ni es th ha
anali st certifica tion th sea rch na lyst resp sibl th pa ratio th sea rch epo rt micha el pe tu sky cfa ere ce rtifi
view ab th comp th eir secu riti exp ress th ep ort accur ate refl ct pe rson al op inion nalyst lso
certifi th art com pen satio dire ctli dire ctli ela te sp ecif reco mme nda tion view co ntain ed th rep
rese arch nal yst cl ud ing volv pr ep ara ti rep ort ceiv ire ct co mp ensa tion con nectio fi rm
stm en king activ na lyst co mpe nsatio wh ich de sala ry us ba sed num ero us factor inclu di ng
stock price pe rform anc ua liti ana lysi inv sto clie nt feed ba ck ro fita bili ty fir im pac te
 fir ms busi ness activiti nd cl ud es mon oth er thin gs nstitut al qui ty trad ing nve stme nt ba nkin se rvice
investm nt ba nkin ser vice de fine un de na rul inclu de mon oth er thin gs actin un de rwrite emb er
selli ng gro se curi tie nde rwriti ng alyst spo nsib le th por mich ae pe tuski cfa emb er th al yst
ho use ho ld oe ot wn sha th co mmo stock co mpa ny na sd gul atio ad op te ule th pr oh ibi sea rch na lyst
tra din se curiti co vere co mpa nie uri ng sp ecifi ti pe rio ds fore nd aft ub licatio rese ar ch rep ts
 arri ngto sea rch sso ciat inc fu ll-se rvice fin cial se rvice firm th offer wid var ieti ser vice ro duct clie nt
rs sho uld ssu rrin gton rese ar ch seeki ng seek inv stme nt king oth er busi ness relat ship
comp un de ts rese arc co vera ge arr ing ton rese arch ceiv nvestm nt king -re late co mp ensa ti
comp wi th pa st th oe xp ect wi thin th ne xt thre mo nth
barrington research associ inc finra-regist broker/deal clear wedbush secur fulli
disclos basi conveni client offer sever way client facilit payment
trade barrington research order may place trade desk
trader michael hutchison head trader christoph pari email address
instant messeng address brrrmh
trade broker trade may also stepped-in barrington research trade execut broker
commiss share arrang barrington commiss share agreement numer broker wall
street complet list commiss share program barrington research particip pleas contact
salesperson trade desk
follow list provid barrington research trade alloc settlement id wedbush dtc code
question trade set account relat inform pleas call trade depart
inform contain herein obtain sourc believ reliabl guarante accuraci complet
opinion estim reflect best judgment report date subject chang without notic report intend inform
purpos constitut offer solicit buy sell secur barrington research associ inc affili offic
analyst employe may time time posit secur refer herein barrington research associ inc may act
princip agent buyer seller purchas sale secur mention report barrington research associ
inc may provid may seek provid invest bank servic compani mention report report may
reproduc form without prior written consent barrington research associ inc right reserv member finra/sipc
